Literature DB >> 22287658

Liver cell transplantation in severe infantile oxalosis--a potential bridging procedure to orthotopic liver transplantation?

Bodo B Beck1, Sandra Habbig, Katalin Dittrich, Dirk Stippel, Ingrid Kaul, Friederike Koerber, Heike Goebel, Eduardo C Salido, Markus Kemper, Jochen Meyburg, Bernd Hoppe.   

Abstract

BACKGROUND: The infantile form of primary hyperoxaluria type I (PHI) is the most devastating PH subtype leading to early end-stage renal failure and severe systemic oxalosis. Combined or sequential liver-kidney transplantation (LKTx) is the only curative option but it involves substantial risks, especially in critically ill infants. The procedure also requires resources that are simply not available to many children suffering from PHI worldwide. Less invasive and less complex therapeutic interventions allowing a better timing are clearly needed. Liver cell transplantation (LCT) may expand the narrow spectrum of auxiliary measures to buy time until LKTx for infants can be performed more safely.
METHODS: We performed LCT (male neonate donor) in a 15-month-old female in reduced general condition suffering from systemic oxalosis. Renal replacement therapy, initiated at the age of 3 months, was complicated by continuous haemodialysis access problems. Living donor liver transplantation was not available for this patient. Plasma oxalate (Pox) was used as the primary outcome measure.
RESULTS: Pox decreased from 104.3±8.4 prior to 70.0±15.0 μmol/L from Day 14 to Day 56 after LCT. A significant persistent Pox reduction (P<0.001) comparing mean levels prior to (103.8 μmol/L) and after Day 14 of LCT until LKTx (77.3 μmol/L) was seen, although a secondary increase and wider range of Pox was also observed. In parallel, the patient's clinical situation markedly improved and the girl received a cadaveric LKTx 12 months after LCT. However, biopsy specimens taken from the explanted liver did not show male donor cells by amelogenin polymerase chain reaction.
CONCLUSIONS: With due caution, our pilot data indicate that LCT in infantile oxalosis warrants further investigation. Improvement of protocol and methodology is clearly needed in order to develop a procedure that could assist in the cure of PHI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22287658     DOI: 10.1093/ndt/gfr776

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

Review 1.  Primary hyperoxalurias: diagnosis and treatment.

Authors:  Efrat Ben-Shalom; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-12-18       Impact factor: 3.714

Review 2.  An update on primary hyperoxaluria.

Authors:  Bernd Hoppe
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

Review 3.  Cell-based liver therapies: past, present and future.

Authors:  Valeria Iansante; Anil Chandrashekran; Anil Dhawan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

4.  Hepatocyte Transplantation in Special Populations: Clinical Use in Children.

Authors:  Zahida Khan; Stephen C Strom
Journal:  Methods Mol Biol       Date:  2017

5.  Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Sachi R Chaudhari; Jing Han; Chelsea M Peterson; Robert T Warren; Madison M Hart; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-11-22       Impact factor: 5.426

Review 6.  Primary hyperoxaluria type 1: practical and ethical issues.

Authors:  Pierre Cochat; Jaap Groothoff
Journal:  Pediatr Nephrol       Date:  2013-03-14       Impact factor: 3.714

Review 7.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

Review 8.  Human hepatocyte transplantation for liver disease: current status and future perspectives.

Authors:  V Iansante; R R Mitry; C Filippi; E Fitzpatrick; A Dhawan
Journal:  Pediatr Res       Date:  2017-12-06       Impact factor: 3.756

Review 9.  Perspectives in primary hyperoxaluria - historical, current and future clinical interventions.

Authors:  Kevin Shee; Marshall L Stoller
Journal:  Nat Rev Urol       Date:  2021-12-08       Impact factor: 16.430

10.  Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived Hepatocytes for Cell-Based Therapy.

Authors:  Samuel J I Blackford; Soon Seng Ng; Joe M Segal; Aileen J F King; Amazon L Austin; Deniz Kent; Jennifer Moore; Michael Sheldon; Dusko Ilic; Anil Dhawan; Ragai R Mitry; S Tamir Rashid
Journal:  Stem Cells Transl Med       Date:  2018-11-19       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.